Reaction

Parainfluenzae Virus Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,528 reports · 105 co-occurring drugs

As of the last recalculation, Parainfluenzae Virus Infection appears in 1,528 FAERS reports alongside 105 co-occurring drug terms. The strongest observed disproportionality signal is PEGASPARGASE (PRR 170.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Pegaspargase	139	170.0	172.0
Mercaptopurine	169	149.1	150.6
Thiotepa	53	78.3	78.7
Filgrastim	162	65.5	65.8
Cytarabine	235	62.8	63.0
Mesna Injection	36	60.8	61.0
Mesna	36	59.6	59.9
Vincristine Sulfate	116	58.3	58.5
Fludarabine Phosphate	119	44.6	44.8
Posaconazole Delayed-Release	33	41.8	41.9
Anti-Thymocyte Globulin (Rabbit)	23	39.4	39.5
Melphalan Hydrochloride	68	38.6	38.7
Posaconazole	44	38.0	38.1
Etoposide	180	37.7	37.8
Melphalan	58	36.1	36.2
Alemtuzumab	47	34.1	34.2
Anti-Itch	150	33.7	33.8
Anti-Pruritic	150	33.7	33.8
Antipruritic (Anti-Itch)	150	33.7	33.8
Cool Relief Gel With Aloe	150	33.7	33.8
Drs. Hydrocortisone	150	33.7	33.8
Hydrocortisone Continuous Spray	150	33.7	33.8
Hydrocortisone Spray	150	33.7	33.8
Anti-Itch Cream	150	33.7	33.8
Hydrocortisone Lotion	150	33.7	33.8
Hydrocortisone Cream 1%	150	33.7	33.7
Hydrocortisone Cream 1/2%	150	33.7	33.7
Hydrocortisone 1%	150	33.6	33.7
Hydrocortisone Cream	150	33.5	33.6
Palivizumab	36	32.7	32.7
Valganciclovir Hydrochloride Powder,	28	31.8	31.9
Hydrocortisone Acetate	151	31.3	31.4
Cyclophosphamide Injection, Solution	283	26.5	26.5
Cyclophosphamide	283	26.5	26.5
Cyclophosphamide For Injection	283	26.5	26.5
Hydrocortisone	156	26.4	26.4
Hydrocortisone Sodium Succinate	17	24.9	24.9
Sirolimus	24	24.6	24.7
Busulfan	27	23.8	23.8
Atovaquone	13	22.2	22.2
Daratumumab	61	21.6	21.7
Valganciclovir	29	21.3	21.4
Valganciclovir Hydrochloride	29	21.3	21.4
Nystatin	39	19.9	19.9
Nystatin Ointment	37	19.7	19.7
Nystatin Cream	37	19.6	19.7
Axicabtagene Ciloleucel	14	19.5	19.5
Human Immunoglobulin G	27	18.1	18.2
Dexamethasone 1.5 Mg	302	17.3	17.3
Methylprednisolone	157	17.1	17.1
Dexamethasone	302	17.0	17.1
Polatuzumab Vedotin	11	15.5	15.5
Carfilzomib	31	15.2	15.2
Tacrolimus Extended-Release Capsules	128	15.1	15.2
Tacrolimus Ointment 0.1%	127	15.1	15.1
Hydroxyurea	23	15.0	15.0
Dornase Alfa	21	14.8	14.8
Lumacaftor And Ivacaftor	9	14.4	14.4
Mycophenolate Mofetil	130	14.2	14.2
Mycophenolate Mofetil Hydrochloride	130	14.1	14.1
Azacitidine For	18	13.6	13.6
Ganciclovir	10	13.4	13.4
Tacrolimus	140	13.3	13.3
Thiamine Hydrochloride	12	13.2	13.2
Ganciclovir Sodium	10	12.9	13.0
Voriconazole Injection	20	12.7	12.7
Sulfamethoxazole And Trimethoprim	75	12.7	12.7
Efavirenz	10	12.3	12.3
Vigabatrin	13	12.2	12.3
Acyclovir	93	11.7	11.8
Selinexor	7	11.1	11.1
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	8	10.9	10.9
Dexamethasone Sodium Phosphate	8	10.8	10.8
Azacitidine	23	10.7	10.7
Voriconazole	23	10.5	10.5
Valacyclovir	31	10.3	10.3
Teduglutide	10	10.2	10.2
Leucovorin Calcium	14	10.1	10.1
Ursosiol	14	9.9	9.9
Thalidomide	25	9.4	9.4
Valacyclovir Hydrochloride	47	9.3	9.3
Blinatumomab	7	9.2	9.2
Venetoclax	40	9.1	9.1
Clobazam	16	9.0	9.0
Ruxolitinib	46	9.0	9.0
Bortezomib	57	9.0	9.0
Ursodiol	14	8.8	8.8
Ixazomib	18	8.6	8.6
Doxorubicin	54	8.5	8.5
Phenobarbital	9	8.5	8.5
Entecavir	7	8.2	8.2
Darunavir	9	8.1	8.2
Tobramycin Solution	7	8.0	8.0
Pomalidomide	57	7.8	7.8
Tobramycin Sulfate	7	7.7	7.7
Amikacin	9	7.2	7.2
Oseltamivir	4	6.9	6.9
Cannabidiol	11	6.4	6.4
Ifosfamide	10	6.4	6.4
Tobramycin	11	6.3	6.3
Temozolomide	9	5.8	5.8
Bosentan	19	5.2	5.2
Ivacaftor	3	5.2	5.2
Lenalidomide	134	4.6	4.6
Elexacaftor, Tezacaftor, And Ivacaftor	4	4.4	4.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.